BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19300417)

  • 1. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
    Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS
    Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
    Yang XY; Xi MR; Yang KX; Yu H
    Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors.
    Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S
    Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis.
    Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM
    Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
    Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
    J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.
    Ambrogi F; Biganzoli E; Querzoli P; Ferretti S; Boracchi P; Alberti S; Marubini E; Nenci I
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):781-90. PubMed ID: 16467089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
    Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of hormonal receptor status of malignant ovarian tumors.
    Tkalia IG; Vorobyova LI; Svintsitsky VS; Nespryadko SV; Goncharuk IV; Lukyanova NY; Chekhun VF
    Exp Oncol; 2014 Jun; 36(2):125-33. PubMed ID: 24980769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
    Lee P; Rosen DG; Zhu C; Silva EG; Liu J
    Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
    Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
    Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
    Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
    Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.
    Gryshkova V; Goncharuk I; Gurtovyy V; Khozhayenko Y; Nespryadko S; Vorobjova L; Usenko V; Gout I; Filonenko V; Kiyamova R
    Exp Oncol; 2009 Mar; 31(1):37-42. PubMed ID: 19300415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.